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Cancer:
 Disease of cells
 disruption of the orderly process of cell growth
 main causes of death after cardiovascular disease
 Cancer is the third main cause of death in Iran (1)
http://www.toilet-related-ailments.com/images/xprostate-cancer-
chart.jpg.pagespeed.ic.wOUqN_JLCY.jpg
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Cancer has two aspects:
 Environment (about 90 %)
 Genetics (about 10%)
 Environmental causes such as smoking, diet and obesity, radiation, 
infection, stress, lack of physical activity and environmental pollution
 Genetic factors can be classified into two groups:
1. Oncogenes     lead to cell growth
2. Tumor suppressor                    an important role in controlling cell 
growth and division.
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 The most important oncogenes such as:
ERK ,MYC,WNT,RAS and TRK, FOS, and PML-RAR
 The most important Tumor suppressor such as: 
p15,p16,p18,p19,p21,p27 and  p53
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Genomic changes in cancer     
causing mutation
Production oncogenic genes with dominant performance 
The loss of the tumor suppressor gene function 
abnormal and excessive cell growth 
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Other factors has a role in cancer development: (2)
 Epigenetic changes including hyper methylation and methylation in 
the DNA and histones, the acetylation/deacetylation of histones, and 
the packing of chromatin into euchromatic and heterochromatic 
regions 
 reduced DNA methylation                     chromosomal instability
 Hayper methylation  DNA                    silencing of tumor  
suppressor genes, such 
as VHL,BRCA1 and LKB1.
Irregularities in the cell cycle A very important factor in 
the pathology of cancer.
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Crosstalk between genomic and epigenetic abnormalities during cancer 
development.
During its progression, external factors cause additional genetic and 
epigenetic changes 8
REPROGRAMING?
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 first experimental of tumor reversibility(3)
 Braun, 1959
 grafted the shoots from crown-gall teratoma 
cells serially to the cut stem ends of the healthy 
tobacco plants.
 The grafted teratoma tissue gradually 
developed more normal appearing shoots
 ‘the cellular alteration in crown gall did not 
involve a somatic mutation at the nuclear gene 
level and rather some yet uncharacterized 
cytoplasmic entity is responsible for the cellular 
changes 
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cancer cells are first reprogrammed 
to pluripotency:
11
12http://acepain.com/wp-content/uploads/2014/01/srem-cell-what-is-it.jpg
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http://image.slidesharecdn.com/stemcellsanditsapplications-150208084647-
(1) Nuclear transfer(NT) 
injection of a somatic 
nucleus into an enucleated 
oocyte, can give rise to 
genetically matched 
embryonic stem (ES) cells 
(“somatic cell nuclear 
transfer,” SCNT). 
(2) a somatic cell is fused with 
an embryonic stem cell 
(ESC).
(3) Explantation of somatic 
cells in culture selects for 
immortal cell lines that may 
be pluripotent or 
multipotent.
(4) Transduction of somatic 
cells with defined factors 
can initiate reprogramming 
to a pluripotent state.
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Nuclear transplantation (NT): (4)
 Hochedlinger et al(2004)
 whether the reprogramming activity of the oocyte can reverse 
the cancer phenotype of a tumor genome and establish 
developmental pluripotency
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Reprogramming of a melanoma 
genome by nuclear transplantation:
 the nuclei of many cancer cells were able to support preimplantation development into 
normal-appearing blastocysts 
 the malignant phenotype of these tumor types can be suppressed by the oocyte 
environment and permit apparently normal early development.
 Furthermore, ES cells derived from one of the cloned melanoma cells were able to 
differentiate into most if not all somatic cell lineages including fibroblasts, 
lymphocytes, and melanocytes.
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Reprogramming of somatic cells to 
pluripotency by OSKM: (5)
 Takahashi & Yamanaka, 2006
 induced pluripotent stem (iPS) cells:
 not need oocytes or blastocyst
 somatic cells (such as fibroblasts, blood cells, etc.) reprogrammed into a pluripotent ES-
like cells 
 transcription factors such as Oct4, Sox2, Klf4, and c-Myc (OSKM)
 four factors must be expressed for more than 12 days in order to generate iPS cells
 epigenetic events such as chromatin modifications or changes in DNA methylation that 
eventually result in the pluripotent state
 much more accessible technique and it side-steps ethical issues associated with using early 
human embryos
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fibroblasts initiates the conversion to partially reprogrammed cells 
that express Fbx15 or to fully reprogrammed iPS cells that express 
Oct4 or Nanog. 
http://ars.els-cdn.com/content/image/1-s2.0-S0092867408001153-gr2.jpg
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 The pluripotency of human iPS cells 
can be validated by cell markers, 
genomic RNA expression profiles, 
epigenetic profiles, and teratoma assays
 Reprogramming Involves Sequential 
Activation of Pluripotency Markers 
and Stochastic Epigenetic Events
 Alkaline phosphatase (AP) and SSEA1 
positive cells are already detected 3 
and 9 days, Oct4 or Nanog appear only 
after 2 weeks. The virally transduced 
factors need to be expressed for about 2 
weeks to initiate the reprogramming 
process.(6) http://ars.els-cdn.com/content/image/1-
s2.0-S0092867408001153-gr3.jpg
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Which of the original factors are 
essential for the reprogramming 
process? (7)
 Oct4 and Sox2 are essential for pluripotency
 Nanog may function to stabilize the pluripotent state
 absence of c-myc transduction:low efficiency
 c-myc significantly enhances and accelerates the process but is 
dispensable
 Oct4, Sox2, and lin28, an RNA-binding protein:only obligatory factor to 
initiate reprogramming and that other factors serve to accelerate the 
process and to increase efficiency.
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http://ars.els-cdn.com/content/image/1-s2.0-S0092867408001153-gr5.jpg
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 transcription factors 
contribute to 
pluripotency in human 
and murine ES cells
Oct4, Sox2, and Nanog are 
also occupied by the 
Polycomb group 
(PcG) proteins
epigenetic regulators: 
 condensation of 
chromatin structure
 gene silencing
Reprogramming of chronic myeloid 
leukemia ( CML ): (3)
 Carette et al (2010)
 originates from hematopoietic stem cells of the bone marrow, is 
caused by a BCR-ABL fusion mutation 
 dependency of CML on BCR-ABL activated tyrosine kinase
 tyrosine kinase inhibitors(TKI) : imatinib
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Reprogramming of chronic myeloid 
leukemia ( CML ):
 iPSCs derived from human chronic myeloid leukemia cells
 reprogramming factors (Oct3/4, Sox2, Klf4 and cMyc)
 parental cell line was strictly dependent on continuous signaling 
of the BCR-ABL oncogene
 reprogrammed cells lost this dependency and became resistant to 
the BCR-ABL inhibitor imatinib
 oncogenic mutations can be dynamically expressed when cancer 
cells are converted to pluripotency and then re-differentiated.
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Reprogramming of gastrointestinal 
cancer cell lines : (9)
 Miyoshi et al (2010)
 would allow the cells to undergo 
differentiation and enhanced sensitivity to 
therapeutics.
 gastrointestinal cancer-derived iPS cells, 
upon differentiation, expressed higher 
levels of the tumor suppressor genes p16 
Ink4a and p53, slower proliferation and 
were sensitive to differentiationinducing
treatment
 pluripotency state imposed by the OSKM 
factors can partially suppress the cancer 
phenotype in the gastrointestinal cell lines.
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Reprogramming human sarcoma cell 
lines: (11)
 OSKM along with NANOG and LIN28
 sarcoma-iPS-derived tumors: lower grade
exhibited more necrosis
reduced staining for a marker of proliferation
reduced expression of the marker than tumors from the 
sarcoma parental cell lines   
reprogramming decreased the aggressiveness of the cancer compared to the cells’ parental 
counterparts. 
All 32 oncogenes and 82 tumor suppressor genes whose promoter DNA was initially 
methylated, were demethylated as a result of reprogramming, indicating that the 
reprogramming process was accompanied by major epigenetic changes in growth- and 
cancer-related genes 25
Reprogramming of glioblastoma
(GBM) neural stem cells: (11)
 (Stricker et al, 2013). 
 reprogrammed using piggyBac transposon vectors expressing OCT4 
and KLF4
 GBM-iPSC into neural progenitors resulted in highly malignant 
cells when injected into immunocompromised mice. 
 GBM-iPSC did not exhibit the malignant phenotype .
 genetic mutations render the cells malignant only when a particular 
cell type with the unique epigenetic state is met.
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problems:
 process of iPS cell generation; 
use of retroviral transgenes 
use of oncogenes (e.g., c-Myc and Klf4). 
Retroviral transfection is the only effective means 
to deliver the four full-length genes into a targeted 
somatic cell
random insertion of retroviral vectors into the 
transfected cell genome may also affect other 
nontargeted genes and produce unexpected results..
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microRNA:
 small non-coding RNA molecule (ca. 22 nucleotides)
 found in plants and animals
 functions : transcriptional and post-transcriptional regulation of gene 
expression. 
 Encoded by eukaryotic nuclear DNA
 miRNAs function via base-pairing with complementary sequences 
within mRNA molecules, usually resulting in gene silencing via 
translational repression or target degradation
 miRNAs can function as tumour suppressors and oncogenes: ‘oncomirs’
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mir-302s:
mir-302s : one of the key 
factors essential for 
maintenance of ES cell renewal 
and pluripotency
The mir-302 microRNA 
(miRNA) family (mir-302s) is 
expressed most abundantly in 
slow-growing human 
embryonic stem (ES) cells, and 
quickly decreases after cell 
differentiation and proliferation. 
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MicroRNAs Induce Epigenetic Reprogramming 
and Suppress Malignant Phenotypes of Human 
Colon Cancer Cells: (12)
miR-302s and miR-369s :
induce cellular reprogramming
modulate malignant phenotypes of human 
colorectal cancer
Mir-302 reprograms human skin cancer cells into a pluripotent
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mir-302s: 
 induced epigenetic modulations of histones and DNA induction of 
cancer cell apoptosis(mitochondrial Bcl2 protein family.)
 attenuate the expression of their predicted target transcription 
factors, such as SP3, HMG-box, forkhead-box, and LIM-homeobox
gene families, to provide the cell reprogramming effect..
small RNAs are unlikely to be incorporated into DNA strands in the nucleus:
reprogramming strategy may be worth considering as a novel future treatment 
strategy
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Advantage:
 transfection of a single mir-302s–expressing transgene:very
simple, efficient, and safe method 
 mir-302s transgene ∼1 kb:
the transfection efficiency is extremely high (∼100%) 
positive mirPS cells selected FACS flow cytometry
transfection and cultivation of mirPS cells :feeder-free condition 
without the risk of feeder antigen contamination.
 no oncogene is used for mirPS cell generation. 
 use electroporation in place of retroviral transfection to deliver 
the single mir-302 transgene, preventing the risk of random viral 
insertion into the host cell genome.
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